期刊文献+

蛋白质组学技术分析肝癌细胞HCCLM3的细胞外蛋白降解组

Degradomic analysis of extracellular proteins of hepatocellular carcinoma cell line hcclm3 using proteomic approach
原文传递
导出
摘要 目的:分析肝癌细胞系HCCLM3的细胞外蛋白降解组,筛选肝癌标记物。方法:凝胶电泳分离HCCLM3细胞外蛋白,线性离子阱-傅立叶变换离子回旋共振质谱(LTQ-FT-MS/MS)对其鉴定,数据库检索结合分子质量分析其降解组。免疫杂交定量骨桥蛋白(OPN)在正常、乙肝、乙肝肝硬化和肝癌4组血清中的表达。结果:HCCLM3细胞外蛋白电泳共测得51个条带,鉴定出1 405种非冗余蛋白,其中474种蛋白发生降解,且分泌蛋白的降解率最高(50%)。肝癌患者血清中OPN 20 kD片段明显高于其余3组(P<0.05),受试者工作特征曲线(ROC)显示AFP对肝癌诊断的曲线下面积(AUC)为0.79,OPN 20 kD片段的AUC为0.68,两者结合后能提高AUC至0.89。结论:凝胶电泳结合质谱技术研究肝癌蛋白降解组有效可行,骨桥蛋白20 kD片段可能对肝癌的诊断具有价值。 Objective: To analyze the degradome of extracellular proteins of hepatocellular carcinoma(HCC) cell line HCCLM3 through proteomic techniques,so as to screen a marker for HCC. Methods: Extracellular proteins of HCCLM3 were resolved by polyacylamide gel electrophoresis(PAGE),and were then identified by using Linear Ion Trap Quadrupole-Fourier Transform-Mass Spectrometry(LTQ-FT-MS/MS) after in-gel digestion.The degradome was analyzed through on-line database searching combined with molecular weight information.The osteopontin(OPN) expression in the plasma of healthy subjects,hepatitis B,hepatitis B-caused cirrhosis and HCC patients were quantified by Western blot method. Results: The HCCLM3 extracellular proteins were resolved into 51 bands and 1 405 non-redundant proteins were identified,Among which 474 proteins were degradated,and the secretory proteins had the highest degradation ratio(50%).The serum level of 20-kD fragment of OPN was significantly higher in HCC patients than that in other three populations.The receiver operating characteristic(ROC) showed the area under curve(AUC) of AFP for HCC diagnosis was 0.79 and 20-kD fragment of OPN was 0.68,respectively,and the combination of the two could raise the AUC to 0.89. Conclusion: The combination use of gel electrophoresis and MS is an effective and feasible approach to investigate the HCC degradome.The 20-kD fragment of OPN may be a potential marker for HCC diagnosis.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2012年第7期807-810,共4页 China Journal of General Surgery
基金 广东省自然科学基金资助项目(9151008901000186)
关键词 肝细胞 骨桥蛋白 蛋白质组学 降解组 Carcinoma Hepatocellular Osteopontin Proteomics Degradome
  • 相关文献

参考文献13

  • 1El-Serag HB. Hepatocellular carcinoma[J]. N Engl J Med, 2011,365 (12):1118-1127.
  • 2Llovet JM, Pena C, Lathia C, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2012.[Epub ahead of print].
  • 3杨建青,潘光栋,刘振,褚光平,刘强,肖亿,袁林.HBx蛋白诱发人肝细胞恶性表型的蛋白组学比较分析[J].中国普通外科杂志,2010,19(8):881-884. 被引量:3
  • 4冯钜涛,刘银坤,代智,周海军,宋海燕,钦伦秀,金红,陆豪杰,汤钊猷.血清蛋白质组分析技术筛选肝癌自发抗体[J].中华肝脏病杂志,2005,13(11):832-835. 被引量:13
  • 5Shen Y, Tolic N, Liu T, et al. Blood peptidome-degradome profile of breast cancer[J]. PLoS One, 2010, 5(10):e13133.
  • 6Ugalde AP, Ordonez GR, Quir o s PM, et al. Metalloproteases and the degradome[J]. Methods Mol Biol, 2010, 622:3-29.
  • 7Stokes A, Joutsa J, Ala-Aho R, et al. Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2010, 16(7):2022-2035.
  • 8Lee JY, Kim JY, Park GW, et al. Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma[J]. Mol Cell Proteomics, 2011, 10(12):M111.009290.
  • 9Kanmura S, Uto H, Sato Y, et al. The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma[J]. J Gastroenterol, 2010, 45(4):459-467.
  • 10Ahmed M, Behera R, Chakraborty G, et al. Osteopontin: a potentially important therapeutic target in cancer [J]. Expert Opin Ther Targets, 2011, 15(9):1113-1126.

二级参考文献26

  • 1Liaw L, Birk DE, Ballas CB, et al. Altered wound healing in mice lacking a functional osteopontin gene ( Spp 1 ) [ J ]. J Clin Invest, 1998 , 101 (7) : 1468 - 1478.
  • 2Hirama M, Takahashi F, Takahashi K, et al, Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth [ J ]. Cancer Lett, 2003, 198 (1) :107 -117.
  • 3Yokosaki Y, Matsuura N, Sasaki T, et al. The intergrin a9131 binds to a novel recognition sequence ( SVVYGLR ) in the thrombincleaved amino-terminal fragment of osteopontin [J]. J Biol Chem,1999,274(51) :36328 -36334.
  • 4Tuck AB, Arsenault DM, O' Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial ceils [ J ]. Oncogene, 1999,18(29) :4237 -4246.
  • 5Feng F, Rittling SR. Mammary tumor development in MMTV- c-mye/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency [ J ] . Breast Cancer Res Treat, 2000,63 (1):71 -79.
  • 6Chang PL, Cao M, Hicks P. Osteopontin induction is required for tumor promoter induced transformation of preneoplastic mouse cells [ J ]. Carcinogenesis, 2003 , 24 ( 1 ) : 1749 - 1758.
  • 7Furger KA, Allan AL, Wilsow SM, et al. β3 integrin expression increases breast carcinomc cell responsiveness to the malignancy enhancing effects of osteopontin [ J]. Mol Cancer Res,2003,1010(8) :810 -819.
  • 8Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phcnotype : evidence for a Ras-activated enhancer in the human OPN promoter[ J] . Clin Exp Metastatic ,2003 ,20( 1 ) :77 - 84.
  • 9Weber GF. The metastasis gene osteopontin : a candidate target for cancer therapy [ J ] . Biochem Biophys Acta, 2001 , 1552 (1):61 -85.
  • 10Gotoh M, Sakamoto M, Kanetaka K, et al. Overexpression of osteopontin in hepatocellular carcinoma [ J ]. Pathol Int, 2002,52(1) :19 -24.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部